Home Tags GlycoConnect

Tag: GlycoConnect

Novel Linker-Drug Technology Enables Antibody-Drug Conjugates with an Expanded Therapeutic Window

Preclinical data from a novel, proprietary ADC technology platform being developed by ProfoundBio was being presented at the 2021 Molecular Targets and Cancer Therapeutics...

MRG004A Enters Clinical Development for the Treatment of Solid Tumors

MRG004A, an antibody-drug conjugate targeting human tissue factor to treat solid tumors, has entered clinical trials in the United States.  The investigational agent, being...

In vivo data Shows Efficacy of Synaffix’ Proprietary Exatecan Linker-Payload to...

In a poster presented during the virtual World ADC meeting, being held September 15 - 17, 2020 scientists at Synaffix showed early in vivo...

Synaffix and ADC Therapeutics Expand Collaboration

The Netherlands-based biotechnology company Synaffix and Swiss-based ADC Therapeutics have expanded the existing collaboration between the companies to explore additional applications of Synaffix’ site-specific...
Featured Image - Laboratory. Courtesy 2019 Fotolia

Shanghai Miracogen and Synaffix Confirm Expansion of License Agreement

Netherlands-based biotech company Synaffix earlier today confirmed the expansion of a license agreement with Shanghai Miracogen, a Chinese biotechnology company with a clinical-stage pipeline...

Abzena Confirms Successful Technical Transfer of Synaffix’s GlycoConnect™ and HydraSpace™ Technologies

Earlier today Abzena confirmed that it had successfully completed a technology transfer and scalability evaluation using the Synaffix's technologies of GlycoConnect™, site-specific antibody-drug conjugation...
Scientist pipetting

ADC Therapeutics Expands Agreement with Synaffix

The Netherlands-based biotechnology company Synaffix, which develops clinical-stage technologies for the development of best-in-class antibody-drug conjugates or ADCs, confirmed that ADC Therapeutics has triggered...

Dutch Biotech Signs License Agreement with Chinese ADC Developer

The Dutch biotech company Synaffix has signed a license agreement with the Chinese ADC developer Shanghai Miracogen. The agreement is estimated to be worth...

First Patient Dosed in Phase I Trial with Pyrrolobenzodiazepine-based Antibody-drug conjugate...

The development of proprietary, pyrrolobenzodiazepine-based, antibody-drug conjugates or ADCs targeting AXL, has entered a news phase with the dosing of the first patient in...

Mersana Therapeutics Focuses its Resources on Advancing XMT-1536, its First-in-Class ADC...

Mersana Therapeutics, a clinical-stage biopharmaceutical company developing a pipeline of antibody-drug conjugates or ADCs designed to target cancers in areas of high unmet need,...

X